Prometheus Biosciences develops and commercializes pharmaceutical and diagnostic products to help physicians individualize patient care.
Prometheus Biosciences, Inc., former Prometheus Laboratories, Inc., a specialty pharmaceutical company, engages in developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. It markets and promotes Entocort EC, a glucocorticosteroid, which is indicated for the induction and maintenance of clinical remission in mild to moderately active Crohn's disease involving the ileum and/or the ascending colon. It has an agreement to acquire rights to LOTRONEX tablets, which is used in female patients with diarrhea-predominant irritable bowel syndrome; and an agreement to develop and commercialize COLAL-PRED, a development-stage product for the treatment of gastrointestinal diseases or other applications. The company also sells other branded drugs, including Imuran for use as an adjunct for the prevention of rejection in kidney transplantation and the management of active rheumatoid arthritis, Helidac Therapy for use together with an H2 antagonist for the eradication of helicobacter pylori bacteria, and Ridaura for the management of rheumatoid arthritis. In addition, Prometheus Laboratories sells a generic formulation of mercaptopurine, which is approved as maintenance therapy for acute lymphatic leukemia as part of a combination regimen through third-party distributors. Further, it provides diagnostic testing services, including specific immunoassays to detect and differentiate diseases, pharmacogenetic testing, and drug metabolite monitoring; and tests that assist physicians in using and monitoring thiopurine drugs and the detection, diagnosis, or treatment of celiac disease, lactose intolerance, and other related disorders. Prometheus Laboratories, Inc. was founded in 1995 and is headquartered in San Diego, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 11, 2021 | IPO | $190M | — | — | — | Detail |
Nov 9, 2020 | Private Equity(PE) | $130M | 10 | Eventide RTW Investments | — | Detail |
Jun 30, 2019 | Series Unknown | $48.06M | — | — | — | Detail |
Nov 28, 2018 | Series Unknown | $10.08M | — | — | — | Detail |
Oct 9, 2017 | Series A | $3.68M | — | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Apr 19, 2022
Loop Health
|
Series B | $25M | Fitness | — |
Jun 8, 2020
Quaise
|
Seed | $6M | Advanced Materials | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Eventide | Yes | Private Equity(PE) |
RTW Investments | Yes | Private Equity(PE) |
Ascend Global Investments | — | Private Equity(PE) |
Cedars Sinai | — | Private Equity(PE) |
Cormorant Capital | — | Private Equity(PE) |
Cowen Healthcare Investments | — | Private Equity(PE) |
Irving Investors | — | Private Equity(PE) |
Nestlé | — | Private Equity(PE) |
Perceptive Advisors | — | Private Equity(PE) |
Point72 | — | Private Equity(PE) |